

This BAF includes the following Principal Risks (PRs) to the Trust's strategic priorities:

- PR1 Significant deterioration in standards of safety and care
- PR2 Demand that overwhelms capacity
- PR3 Critical shortage of workforce capacity and capability
- PR4 Failure to achieve the Trust's financial strategy
- PR5 Inability to initiate and implement evidenced based improvement and innovation
- PR6 Working more closely with local health and care partners does not fully deliver the required benefits
- PR7 Major disruptive incident

#### The key elements of the BAF are:

- A description of each Principal (strategic) Risk, that forms the basis of the Trust's risk framework (with corresponding corporate and operational risks defined at a Trust-wide and service level)
- Risk ratings current (residual), tolerable and target levels
- Clear identification of primary strategic threats and opportunities that are considered likely to increase or reduce the Principal Risk, within which they are expected to materialise
- A statement of risk appetite for each threat and opportunity, to be defined by the Lead Committee on behalf of the Board (**Averse** = aim to avoid the risk entirely; **Minimal** = insistence on low risk options; **Cautious** = preference for low risk options; **Open** = prepared to accept a higher level of residual risk than usual, in pursuit of potential benefits)
- Key elements of the risk treatment strategy identified for each threat and opportunity, each assigned to an executive lead and individually rated by the lead committee for the level of assurance they can take that the strategy will be effective in treating the risk (see below for key)
- Sources of assurance incorporate the three lines of defence: (1) Management (those responsible for the area reported on); (2) Risk and compliance functions (internal but independent of the area reported on); and (3) Independent assurance (Internal audit and other external assurance providers)
- Clearly identified gaps in the primary control framework, with details of planned responses each assigned to a member of the Senior Leadership Team (SLT) with agreed timescales
- risk

Key to lead committee assurance ratings:



Green = Positive assurance: the Committee is satisfied that there is reliable evidence of the appropriateness of the current risk treatment strategy in addressing the threat or opportunity

- no gaps in assurance or control AND current exposure risk rating = target

OR

- gaps in control and assurance are being addressed



Amber = Inconclusive assurance: the Committee is not satisfied that there is sufficient evidence to be able to make a judgement as to the appropriateness of the current risk treatment strategy



Red = Negative assurance: the Committee is satisfied that there is sufficient reliable evidence that the current risk treatment strategy is not appropriate to the nature and/or scale of the threat or opportunity

This approach informs the agenda and regular management information received by the relevant lead committees, to enable them to make informed judgements as to the level of assurance that they can take and which can then be provided to the Board in relation to each Principal Risk and also to identify any further action required to improve the management of those risks.



Principal risk (what could prevent us achieving this strategic priority)	_	n in standards of	n standards of safety safety and quality of patien nes		tantial incidents of		Strategic priority	1. To provide outstanding care		
Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Patient harm	25				
Executive lead	Medical Director	Likelihood	5. Very likely	3. Possible	2. Unlikely	Risk appetite	Minimal	15		——— Current risk level
Initial date of assessment	01/04/2018	Consequence	4. High	3. Moderate 4. High	3. Moderate 4. High	Risk treatment strategy	Modify	10		Tolerable risk level
Last reviewed	08/09/2020	Risk rating	20. Significant	9. Medium 12. High	6. Low 8. Medium			0		····· Target risk level
Last changed	08/09/2020							Mon's Dec's Jan's Febris	Mary Phily Mary Miry Miry Prays ching Oring	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
A widespread loss of organisational focus on patient safety and quality of care leading to increased incidence of avoidable harm, exposure to 'Never Events', higher than expected mortality, and significant reduction in patient satisfaction	<ul> <li>Clinical service structures, accountability &amp; quality governance arrangements at Trust, division &amp; service levels including:         <ul> <li>Monthly meeting of Patient Safety &amp; Quality GroupQuality &amp; Patient Safety Cabinet (PSQGQPSC) with work programme aligned to CQC registration regulations</li> <li>Advancing Quality Programme and AQP oversight group</li> <li>Nursing and Midwifery and AHP Business meeting</li> </ul> </li> <li>Clinical policies, procedures, guidelines, pathways, supporting documentation &amp; IT systems</li> <li>Clinical audit programme &amp; monitoring arrangements</li> <li>Clinical staff recruitment, induction, mandatory training, registration &amp; re-validation</li> <li>Defined safe medical &amp; nurse staffing levels for all wards &amp; departments (Nursing safeguards monitored by Chief Nurse)</li> <li>Ward assurance/ metrics &amp; accreditation programme</li> <li>Nursing &amp; Midwifery Strategy</li> <li>AHP Strategy</li> <li>Scoping and sign-off process for incidents and SIs</li> </ul>	Intranet currently contains some out of date clinical information that may still be accessible	Intranet documents review SLT Lead: Head of Communications Timescale: end August 2020December 2020	Management: DPR Report to PSQG-QPSC monthly and QC bi-monthly; PSQG-QPSC assurance report to QC bi-monthly; AQP Programme report to QC bi-monthly; Learning from deaths Report to QC and Board; Quarterly Strategic Priority Report to Board; Senior leadership walk arounds — 15 steps assurance report to QC Jul '19; Divisional risk reports to Risk Committee bi-annually; Guardian of Safe Working report to Board qrtly; Senior Leadership Walkarounds weekly; Divisional Risk Reports to RC 6-monthly; Patient Safety Culture (PSC) programme; EoLC Annual Report to QC; Safeguarding Annual Report to QC; CYPP report to QC quarterly; Medical Education update report to QC Jul '19  Risk & compliance: Quality Dashboard and SOF to PSQG-QPSC Monthly; Quality Account Report Qtrly to PSQG-QPSC and QC; SI & Duty of Candour report to PSQG-QPSC monthly; CQC report to QC bi-monthly; Significant Risk Report to RC monthly  Independent assurance: CQC Insight tool to PSQG-QPSC monthly; CQC Rating and oversight; IA (360) Transfer of Handover assurance report QC Sep '18; Antenatal & newborn screening peer review QC Nov '18; Sherwood Birthing Unit Audit to PSQG-2018, ICNARC Quarterly Report; SHOT report to PSQG-QPSC 2018; EoLC Audit 2018; PHQA visit for Smoke-free Life; Audit Inpatient Survey 2017; Maternity Inpatient Survey 2018; CQC Insight Tool to PSQG-QPSC monthly and QC bi-monthly; GMC Feedback 2018; NNAP Audit 2018; Care Quality Commission / External Regulation Report to QC Mar '19; Medicines Optimisation Report to QC Mar '19; Medicines Optimisation Report to QC Mar '19	None	Positive



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
An outbreak of infectious	<ul> <li>Infection prevention &amp; control (IPC) programme</li> </ul>	None	N/A	Management: Divisional reports to IPC Committee (every 6 weeks); IPC	Learning from the impact on activity,	
disease (such as pandemic	Policies/ Procedures; Staff training; Environmental			Annual Report to QC and Board; Water Safety Group;	patient safety and staffing due to COVID-	
influenza; Coronavirus;	cleaning audits			<b>Risk &amp; compliance:</b> IPC Committee report to PSQG-QPSC qtrly; SOF	19 wave 1	
norovirus; infections	<ul> <li>PFI arrangements for cleaning services</li> </ul>			Performance Report to Board monthly; IPC Clinical audits in IPCC report		
resistant to antibiotics) that	<ul> <li>Root Cause Analysis and Root Cause Analysis Group</li> </ul>			to <del>PSQG</del> <u>QPSC</u> qtrly	Constraints of critical care capacity and	
forces closure of one or	<ul> <li>Reports from Public Health England received and</li> </ul>			Independent assurance: Internal audit plan; CQC Rating Good with	PPE availability dependent on the size of	
more areas of the hospital	acted upon			Outstanding for Care Aug '18; PLACE Assessment and Scores Estates	future waves and restoration activity	Inconclusive
	<ul> <li>Infection control annual plan developed in line with</li> </ul>			Governance bi-monthly; Public Health England attendance at IPC		
	the Hygiene Code			Committee; Influenza vaccination cumulative number of staff	Business case to enhance oxygen	
	<ul> <li>Influenza vaccination programme</li> </ul>			vaccinated	capacity/flow awaited	
	Public communications re: norovirus and infectious					
	diseases					
	<ul> <li>Coronavirus identification and management process</li> </ul>					



Principal risk (what could prevent us achieving this strategic priority)	PR 2: Demand that ov Demand for services that ov		•	ration in the quality, safe	ety and effectiven	ess of patient care		Strategic priority 1. To provide outstanding care
Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Patient harm	25		
Executive lead	Chief Operating Officer	Likelihood	5. Very likely	4. Somewhat likely	2. Unlikely	Risk appetite	Minimal	20 Current risk level
Initial date of assessment	01/04/2018	Consequence	4. High	4. High	4. High	Risk treatment strategy	Modify	10 Tolerable risk level
Last reviewed	01/09/2020	Risk rating	20. Significant	16. Significant	8. Medium			Target risk level
Last changed	01/09/2020							Haris Decis surge say Maris Baris Maris Miris Miris Miris Sea go Griso

East changed 01/03/	020									
Strategic threat (what might cause this to happen)			<b>Iready</b> have in place to assist us in / impact of the threat)	Gaps in control (Specific areas / issues when further work is required to manage the risk to accepted appetite/ tolerance level)	(are further co	improve control ontrols possible in order to posure within tolerable range?)		surance (and date) ne controls/ systems which we are placing reliance on	Gap in assurance / action to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
Threat: Growth in demand for care caused by an ageing population (forecast annual increase in emergency demand of 4-5% per annum); reduced social care funding and increase acuity leading to more admissions and longer length stay, or a reduction in capacit meet current and future demidue to the impact of COVID-1	Single streaming meetings with Trust and Syst Cancer Improved Trust leadersh Patient pathw Inter-profession turnaround tire day Proactive syste Better Togeth Patient Flow P SFH internal W capacity plan Referral mana secondary care MSK pathways COVID-19 Incides	ng process for ED & NEMs em escalation processement plan ip of and attendance ay, some of which a conal standards acromes such as diagnosem leadership engager Alliance Delivery programme winter capacity planter systems shees	ce at A&E Board are joint with NUH ass the Trust to ensure stics are completed within 1 gement from SFH into Board  & Mid Notts system ared between primary and governance process during COVID-19	National workforce supply in some specialties  Robust delivery of the demand management schemes across the system	shared with SLAs via Str. for joint set On-going despecifically future served evelopments strategy, To Refresh NU 6-monthly  SLT Lead: No Progress: Process and presented.	nical models for services n NUH strengthening of rategic Partnership Board rvices iscussions across ICS and with NUH to describe ice delivery. Continued int of ICS clinical service omorrow's NUH IH/SFH Exec to Exec forum progress updates to Board Medical Director Paper describing the d timescales to be to Board in April TBDend March 2021	arrangement: Executive Teal including upd meetings; Ele Dalton (NHSI) improvement 19/20 to iden Identifying ar COVID-19 Par Recovery Plar Risk & compl Committee by monthly; Sing Performance governance s Independent and capacity Regulatory Fr (Emergency R	the Performance management reporting is between Divisions, Service Lines and arm; Emergency care capacity plan to Board lates on the winter plan Oct '18; Exec to Exec ctive Care Expectations — Response to Ian I Letter to Board Sep '18; Cancer 62 day I plan to Board; Planning documents for tify clear demand and capacity gaps/bridges; and capturing Potential Harm Resultant from and capturing Potential Harm Resultant from and capacity significant Risk Report to Risk i-annually; Significant Risk Report to RC gle Oversight Framework Integrated Monthly Report to Board; Incident Control Team tructure to TMT Mar '20  assurance: IA review of outpatient Demand modelling Jul '18; amework — Performance Standards leadmissions Indicator) Follow-Up Sep '18; e Support Team review of cancer processes	Impact on cancer surgery and screening programmes due to COVID-19	Inconclusive
Threat & Opportunity: Operational failure of General Practice to cope with demand resulting in even higher demand for secondary care as the 'provider of last resort'	operational fa • Engagement in leading role in Weekly Execut	ilure of General Pra	ystem (ICS), and assuming a povider development				and SFH risk r	t: Routine mechanism for sharing of CCG registers – particularly with regard to risks for staffing and demand assurance: 'Drivers of demand' discussed at		Inconclusive
Threat & Opportunity: Drop i operational performance of neighbouring providers that creates a shift in the flow of patients and referrals to SFH	leading role in Horizon scann between relev Weekly manag Notts HC	Integrated Care Proing with neighbour ant Executive Direct	th the Service Director from	None	N/A		partnership fo	<b>pliance:</b> Divisional NUH/SFH strategic orum minutes and action log; NUH service H paper to Executive Team	Lack of control over the flow of patients from the surrounding area	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	PR 3: Critical shortage of war A shortage of workforce capacity a an adverse impact on patient care	and capability res	•	-		Strategic priority	3: To maximise the potential	of our workforce		
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	25		
Executive lead	Director of People	Likelihood	5. Very likely	4. Somewhat likely	3. Possible 2. Unlikely	Risk appetite	Cautious	20		——Current risk level
Initial date of assessment	01/04/2018	Consequence	4. High	3. Moderate 4. High	3. Moderate 4. High	Risk treatment strategy	Modify	10 5	***************************************	Tolerable risk level
Last reviewed	07/10/2020	Risk rating	20. Significant	12. High 16. Significant	98. Medium			0 -19 -20 -20 -20	Mar-20 Apr-20 Jun-20 Jul-20 Aug-20 Sep-20	······ Target risk level
Last changed	21/09/2020							No. Dec	May App May Jur Lur Lur Sep Sep Oct	

assessment					<u>4. підп</u>		<u>4. півп</u>	strategy		. 3		
Last reviewed  Last changed	07/10/2020		Risk rating	20. Significant	12. High 16. Significan	<u>nt</u>	9 <u>8</u> . Medium			O Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 May-20 Jun-20	Jul-20 Aug-20 Sep-20 Oct-20	risk ievei
Last changed	21/09/2020										-	
Strategic threat (what might cause this to				<b>Iready</b> have in place to assist us i f the threat)	in managing (S fu m	Gaps in co Specific areas / urther work is nanage the risk ppetite/ tolera	/ issues where required to to accepted	Plans to improve control are further controls possible in order or reduce risk exposure within tolerable lange?)	(Evidence tha	assurance (and date) at the controls/ systems which we are placing re effective)	Gap in assurance / action to address gap and issues relating to COVID-19	Assurance rating
staff due to demogr (including a significa external factors and circumstances) and attitudes to careers employment marke reduced availability competition) resulti	<ul> <li>People Culture and Improvement Strategy</li> <li>People Culture and Improvement Strategy</li> <li>People Culture and Improvement Strategy</li> <li>People and Inclusion Cabinet</li> <li>Culture and Improvement Cabinet</li> <li>Medical and Nursing task force</li> <li>Activity, Workforce and Financial plan</li> <li>2 year workforce plan supported by Workforce Planning Group and review processes (consultant job planning; workforce modelling; winter capacity plans)</li> <li>Vacancy management and recruitment systems and processes</li> <li>TRAC system for recruitment; e-Rostering systems and procedures used to plan staff utilisation</li> <li>Defined safe medical &amp; nurse staffing levels for all wards and departments / Safe Staffing Standard Operating Procedure</li> <li>Temporary staffing approval and recruitment processes with defined authorisation levels</li> <li>Education partnerships</li> <li>Director of People attendance at People and Culture Board</li> <li>Workforce planning for system work stream</li> <li>Communications issued regarding HMRC taxation rules on pensions and provision of pensions advice</li> <li>Pensions restructuring payment introduced</li> <li>Risk assessments for at-risk staff groups</li> <li>People Culture and Improvement Strategy</li> </ul>		oup and elling;  ses macedures A	ownership and understanding of their workforce issues  Insufficient staff to meet the Phase 3 Activity Plan		mplementation of the People, culture and Improvement trategy (People and Inclusion LT Lead: Director of People imescale: September 2020  Increase staffing to meet the chase 3 Activity Plan LT Lead: Director of People imescale: March 2021	2018/20; C Board; AHI Workforce Quarterly / Inclusion a Culture an May '20; R to Board A Risk and c significant planning re Workforce agency rep working re Independe follow up r NHSI use o	ent: Nursing & Midwifery Strategy Quarterly Strategic Priority Report to P Strategy to Board Sep '19; and OD ICS/ICP update quarterly; Assurance reports on People & and Culture & Improvement to People d Improvement Committee; People d Improvement: COVID-19 Update ecruitment & Retention presentation ug '20 compliance: Risk Committee risk report Monthly; HR & Workforce eport Risk Committee; SOF — Indicators (Monthly); Bank and cort (monthly); Guardian of safe eport to Board Feb '19 ent assurance: Use of e rostering report Apr '18; Well-led report CQC; of resources report; IA Recruitment & report Jan '19 — Significant Assurance	Staff becoming infected, leading to increased sickness absence  Staff working in unfamiliar roles  Staff mental health as a result of psychological trauma	Inconclusive		
Threat: A significant productivity arising reduction in staff avereduction in effort accontractual requires substantial proporti workforce and/or localleagues from the by other factors sucsatisfaction, lack of personal developmer restraint, or workfowellbeing issues, or consistent values ar line with desired cu	from a short-term vailability or a above and beyond ments amongst a ion of the coss of experienced experienced ch as poor job opportunities for ent, on-going pay rce fatigue or failure to achieve and behaviours in	<ul> <li>People and Ind</li> <li>Culture and Im</li> <li>Chief Executive</li> <li>Engagement en Change</li> <li>Schwartz roun</li> <li>Learning from</li> <li>Staff morale in</li> <li>Star of the mo</li> <li>Divisional active</li> <li>Policies (inc. startler)</li> <li>Just and restor</li> </ul>	clusion Cabinet inprovement Cabinet re's blog / Staff Comevents with Staff Net ands COVID dentified as 'profile to both/ milestone ever on plans from staff staff development; a at work policy)	t munication bulletin tworks (BAME, LGBT, WAN risk' in Divisional risk regis nts survey ppraisal process; sickness	sters <u>Li</u> <u>a</u> <u>a</u>	ack of cons pproach to nd wellbeir liscussions	istent Urwelfare de Sur Line d	mplementation of the People, culture and Improvement trategy (Culture and mprovement)  LT Lead: Director of People imescale: September lovember 2020  Introduction of a personally-entred health and wellbeing iscussion process  LT Lead: Director of Culture & mprovement imescale: October 2020	annual rep Inclusion A WDES repo Assurance Annual Rep Assurance Culture & Improvem Improvem Equality & '20; Busine exercise re	ent: Staff survey, action plan and port to Board Jul '20; Diversity & annual report Jun '20; WRES and port to Board Jun '20; Raising Concerns report to Board quarterly; TED port to Board Nov '19; Quarterly reports on People & Inclusion and Improvement to People Culture and lent Committee; People Culture and lent: COVID-19 Update May '20; Diversity presentation to Board Aug less Continuity exercises — post leports through Resilience Assurance le (rolling program)	Reduction in available staff due to COVID-19, e.g. shielding of vulnerable staff groups and social distancing  Reduction in effort above and beyond contractual requirements due to COVID-19 service restrictions  Reluctance of some staff members to return to work due to COVID-19-associated health concerns	Inconclusiv



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19	Assurance rating
This could also lead to lack of engagement with patients, resulting in failure to address patient empowerment and self-help and failure to work across the system to empower patients and carers to enable personalised patient centred care	<ul> <li>Staff wellbeing drop-in sessions</li> <li>Staff counselling / Occ Health support</li> <li>Enhanced equality, diversity and inclusion focus on workforce demographics</li> <li>Freedom to Speak Up Guardian and champion networks</li> <li>Emergency Planning, Resilience &amp; Response (EPRR) arrangements for temporary loss of essential staffing (including industrial action and extreme weather event)</li> </ul>	Inequalities in staff wellbeing across protected characteristics groups	Completion and delivery of WRES and WDES action plans SLT Lead: Director of People Timescale: March 2021	Risk & compliance: Freedom to speak up self-review Board Jan '20; Freedom to Speak Up Guardian report quarterly; Guardian of Safe Working report to Board; Gender Pay Gap report to Board Mar'20; TRAC Performance Report to P, OD&C quarterly; Interim NHS People Plan self-assessment to Board Nov '19; Significant Risk Report to RC monthly Independent assurance: National Staff Survey Nov '19; SFFT/Pulse surveys (Quarterly); Wellled report CQC; EPRR Report (bi-annually) Independent assurance: Confirm and Challenge by NHS England Regional team and CCGs Sep '18; Internal Audit Business Continuity and Emergency Planning Sep '18		



Principal risk (what could prevent us achieving this strategic priority)	PR 4: Failure to achieve		0,		Strategic priority	5: To achieve better value				
Lead Committee	Finance	Risk rating	Current exposure	20						
<b>Executive lead</b>	Chief Financial Officer	Likelihood	3. Possible	3. Possible	2. Unlikely	Risk appetite	Cautious	15		—— Current risk level
Initial date of assessment	01/04/2018	Consequence	5. Very high	4. High	4. High	Risk treatment strategy	Modify	5	***************************************	Tolerable risk level
Last reviewed	29/09/2020	Risk rating	15. Significant	12. High	8. Medium			0		······ Target risk level
Last changed	27/07/2020							Many Decy Jany	est the 10 par to have hur to his post of set to other	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap	Assurance rating
Threat: A reduction in funding or change in financial trajectory or unexpected event resulting in an increased Financial Improvement Plan (FIP) requirement to reduce the scale of the financial deficit, without having an adverse impact on quality and safety	<ul> <li>5 year long term financial model</li> <li>Working capital support through agreed loan arrangements</li> <li>Annual plan, including control total consideration; reduction of underlying financial deficit and unwinding of the PFI benefit by £0.5m annually</li> <li>Engagement with the Better Together alliance programme</li> <li>FIP Board, FIP planning processes and PMO coordination of delivery</li> <li>Delivery of budget holder training workshops and enhancements to financial reporting</li> <li>A full 'wash up' of portfolio planning, delivery and engagement conducted; recovery plan in place, Board approved &amp; governance in place</li> <li>Medical Pay Task Force action plan in place</li> <li>Close working with STP partners and the Alliance framework to identify system-wide cost reductions</li> <li>External management support to deliver the FIP</li> <li>Executive oversight of commitments</li> <li>All costs and required cash associated with COVID-19 will be funded until 31/7/20, and for at least one further month</li> </ul>	No long term commitment received for liquidity / cash support  Lack of identification of opportunities for recurrent delivery of FIP	Full receipt of required cash (FRF) following delivery of NHSI required future trajectories SLT Lead: Chief Financial Officer Timescale: Post COVID-19  Full review of ability to improve recurrent delivery of FIP within financial planning for 2020/21 SLT Lead: Chief Financial Officer Timescale: Post COVID-19  Budget setting process for 2020/21 to include enhanced confirm and challenge SLT Lead: Chief Financial Officer Timescale: Post COVID-19	Management: CFO's Financial Reports & FIP Summary (Monthly); Quarterly Strategic Priority Report to Board Jul '18; Alliance Progress Report & STP FIP (at each Finance Committee meeting); Investment governance work programme; Divisional risk reports to Risk Committee biannually Risk and compliance: Risk Committee significant risk report Monthly; Independent assurance: Internal Audit Report FIP/ QIPP (Jul '18); EY Financial Recovery Plan; all costs associated with COVID-19 will be reimbursed	Awaiting confirmation of the financial regime post 31/07/20	Inconclusive
Threat: System transformation requiring undeliverable cost reductions	<ul> <li>Working within the agreed alliance framework and contracting structures to ensure the true cost of system change is understood and mitigated</li> <li>ICP-wide joint planning process 2019/20</li> <li>Mid-Nottinghamshire planning group and the ICS planning group</li> <li>Senior representatives on all programme delivery Boards (Better Together Boards)</li> <li>Contractual payment mechanism for 2019/20 recognises marginal costs</li> </ul>	Outpatient transformation inability to reduce costs in line with QIPP target		Management: Alliance progress report FC Oct '18; Trust management team meetings; Exec Meetings; CCG meetings; Notts Healthcare Meetings Risk and compliance: planning reports to Finance Committee and Board of Directors Independent assurance: none currently in place	Awaiting confirmation of the financial regime post 31/07/20	Inconclusive



Principal risk (what could prevent us achieving this strategic priority)	PR 5: Inability to initiate and in Lack of support, capability and agility to	•		•		Strategic priority 4: To continuously learn and improve  Current risk level  Tolerable risk level		
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Patient Harm	10		
<b>Executive lead</b>	Director of Culture & Improvement	Likelihood	3. Possible	3. Possible	2. Unlikely	Risk appetite	Cautious	6 ——Current risk level
Initial date of assessment	17/03/2020	Consequence	3. Moderate	3. Moderate	3. Moderate	Risk treatment strategy	Modify	2
Last reviewed	07/10/2020	Risk rating	9. Medium	9. Medium	6. Low			າວ ກວ່າວ ກວ່າວ ກວ່າວ ກວ່າວ
Last changed	03/09/2020							Marin Rating Many Miling Miling Waster Seary Octing

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19	Assurance rating
Threat: Lack of understanding and agility resulting in reduced efficiency and effectiveness around how we provide care for patients	<ul> <li>Digital Strategy</li> <li>Improvement Strategy</li> <li>People, Culture &amp; Improvement Committee</li> <li>Leadership development programmes</li> <li>Talent management map</li> <li>Programme Management Office</li> <li>Culture &amp; Improvement Cabinet</li> <li>Transformation Cabinet</li> </ul>		Establish Innovation and Improvement Forum SLT Lead: Director of Culture and Improvement Timescale: end September 2020 December 2020  Innovation and Improvement to be a core responsibility in all advertised and revised clinical Job Descriptions SLT Lead: Medical Director Timescale: end August 2020 completed	Management: Monthly FIP report to FC; AQP programme report to QC bi-monthly; accelerated implementation of developments in some areas due to the impact of COVID-19; Significant Service Change report to Board Jun '20; Draft transformation programme to Board Jul '20 Risk and compliance: SOF Culture and Improvement indicators Independent assurance: none currently in place	Delays in planned improvement and innovation programmes due to COVID-19	Positive



Principal risk (what could prevent us achieving this strategic priority)	PR 6: Working more closely with local health and care partners does not fully deliver the required benefits  Influencing the wider determinants of health and improving our collective financial position requires close partnership working. This may be difficult because of differences in governance, objectives and appetite for and ability to change.							Strategic priority	4: To continuously learn and improve 2: To promote and support health and wellbeing
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	10	
<b>Executive lead</b>	Chief Executive Officer	Likelihood	3. Possible	4. Possible	2. Unlikely	Risk appetite	Cautious	6	Current risk level
Initial date of assessment	01/04/2020	Consequence	2. Low	2. Low	2. Low	Risk treatment strategy	Modify	2	Tolerable risk level
Last reviewed	30/09/2020	Risk rating	6. Low	8. Medium	4. Low			0 2 2 2 2	Target risk level
Last changed	30/09/2020							Hon, Dec., Jau, Fep.,	Maria Ratia Maria Intig Intig Esta Setti Ottig

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19	Assurance rating
Threat: Conflicting priorities, financial pressures (system financial plan misalignment) and/or ineffective governance resulting in a breakdown of relationships amongst ICS and ICP partners and an inability to influence further integration of services across acute, mental, primary and social care	<ul> <li>Mid-Nottinghamshire Integrated Care Partnership Board</li> <li>Mid-Nottinghamshire ICP Executive formed May 2020</li> <li>Mid-Nottinghamshire ICP breakthrough objectives signed off July 2020</li> <li>Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare</li> <li>Nottingham and Nottinghamshire Integrated Care System Board</li> <li>Continued engagement with ICP and ICS planning and governance arrangements</li> <li>Quarterly ICS performance review with NHSI</li> <li>Joint development of plans at ICS level</li> <li>Finance Directors Group</li> <li>ICS Planning Group</li> <li>Alignment of Trust, ICS and ICP plans</li> <li>Trust CFO role as ICS Finance Director</li> <li>Independent chair for ICP</li> </ul>	Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare have been paused – attempting to restart	ICS governance review to include:  Roles and responsibilities of the ICS Board Governance manual SLT Lead: Chief Executive Officer Timescale: TBCend August 2020 end October 2020  Restore Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare SLT Lead: Chief Executive Officer Timescale: end September 2020	Management: Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Nottingham and Nottinghamshire ICS Leadership Board Summary Briefing to Board; Planning Update to Board Risk & compliance: Significant Risk Report to RC monthly Independent assurance: 360 Assurance review of SFH readiness to play a full part in the ICS – Significant Assurance	Delay in delivering the benefits of system working due to the impact of COVID-19	Inconclusive
Threat and Opportunity: Clinical service strategies and/or commissioning intentions that do not sufficiently anticipate evolving healthcare needs of the local population and/or reduce health inequalities	<ul> <li>Continued engagement with commissioners and ICS developments in clinical service strategies focused on prevention</li> <li>Partnership working at a more local level, including active participation in the mid-Nottinghamshire ICP</li> <li>Clinical Services Strategy - 5 of 20 services complete</li> </ul>	Insufficient granularity of plans to meet the needs of the population and the statutory obligations of each individual organisation	Development of a co-produced clinical services strategy for the ICS footprint – 2 <sup>nd</sup> set of 5 services <b>SLT Lead:</b> Medical Director 5 of 20 services complete as at October 2019 <b>Timescale:</b> end August December 2020	Management: Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Planning Update to Board Independent assurance: none currently in place	Delay in delivering the benefits of system working due to the impact of COVID-19	Inconclusive



Principal risk	PR 7: Major disruptive incident							Strategic priority
(what could prevent us achieving this strategic	A major incident resulting in temporary hospital closure or a prolonged disruption to the continuity of core services across the							1: To provide outstanding care
priority)	Trust, which also impacts significantly on the local health service community							
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	15
Executive lead	Director of Corporate Affairs	Likelihood	3. Possible	3. Possible	1. Very unlikely	Risk appetite	Cautious	10 ——Current risk level
Initial date of assessment	01/04/2018	Consequence	4. High	4. High	4. High	Risk treatment strategy	Modify	5 ———Tolerable risk level Target risk level
Last reviewed	05/10/2020	Risk rating	12. High	12. High	4. Low			0 +
Last changed	05/10/2020							Hours decis purifest of the right hours hiris hiris the gent of right

Last changed 05/10	/2020			To Go to to to the You by You to be the to				
Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19	Assurance rating  Positive		
Threat: A large-scale cyberattack that shuts down the IT network and severely limits the availability of essential information for a prolonged period	<ul> <li>Information Governance Assurance Framework (IGAF) &amp; NHIS Cyber Security Strategy</li> <li>Cyber Security Programme Board &amp; Cyber Security Project Group and work plan</li> <li>Cyber news – circulated to all NHIS partners</li> <li>Network accounts checked after 50 days of inactivity – disabled after 80 days if not used</li> <li>Major incident plan in place</li> <li>Periodic phishing exercises carried out by 360 Assurance</li> <li>Spam and malware email notifications circulated</li> </ul>			Management: Data Protection and Security Toolkit submission to Board Mar '20 - 100% compliance; Hygiene Report to Cyber Security Board monthly; NHIS report to Risk Committee quarterly; IG Biannual report to Risk Committee; Cyber Security and COVID-19 Report to Board May '20 Independent assurance: 360 Assurance Cyber Security Governance Report Jan '19 – Significant Assurance; 360 Assurance Data Security and Protection Toolkit Independent Assessment Mar '20 – High confidence in submission; ISO 27001 Information Security Management Certification	Insufficient assurance regarding governance and interface with NHIS  360 Assurance internal audit of governance and interface – ToRs agreed  SLT Lead: Executive Medical Director  Timescale: End November 2020			
Threat: A critical infrastructure failure caused by an interruption to the supply of one or more utilities (electricity, gas, water), an uncontrolled fire or security incident or failure of the built environment that renders a significant proportion of the estate inaccessible or unserviceable, disrupting services for a prolonged period	<ul> <li>PFI Contract and Estates Governance arrangements with PFI Partners</li> <li>Fire Safety Strategy</li> <li>NHS Supply Chain resilience planning</li> <li>Emergency Preparedness, Resilience &amp; Response (EPRR) arrangements at regional, Trust, division and service levels</li> <li>Operational strategies &amp; plans for specific types of major</li> </ul>	Operational resilience of the Central Sterile Services Department (CSSD)	Surgery division to present the preferred CSSD service provision option to the Executive team SLT Lead: Divisional General Manager - Surgery Timescale: end August 2020October 2020	Management: Central Nottinghamshire Hospitals plc monthly performance report; Fire Safety Annual Report; Condition of retained estate (CCU Water System) update to Risk Committee Jan '19  Risk & compliance: Monthly Significant Risk Report to Risk Committee  Independent assurance: Premises Assurance Model to RC Dec '18; EPRR Report; EPRR Core standards compliance rating (Oct '19) – Substantial Assurance; Water Safety report (WSP) to Joint Liaison  Committee Oct '19; WSP report – hard FM independent audit	Insufficient assurance of hard and soft FM contractor performance  Provide an assurance report on hard and soft FM performance  SLT Lead: Associate Director of Estates & Facilities  Timescale: End September 2020completed  Monitor hard and soft FM performance and provide periodic assurance reports  SLT Lead: Associate Director of Estates & Facilities  Timescale: up to end March 2021  Delays to infrastructure works due to Coronavirus restrictions:  MCH fire works (completion Apr 2021)  Newark T&O Surgery (to commence Aug 2020)	Positive		



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gap in assurance / action to address gap and issues relating to COVID-19	Assurance rating
Threat: A critical supply chain failure that severely restricts the availability of essential goods, medicines or services for a prolonged period	<ul> <li>NHS Supply Chain resilience planning Business Continuity         Management System &amp; Core standards</li> <li>CAS alert system – Disruption in supply alerts</li> <li>Major incident plan in place</li> <li>PPE Strategy</li> <li>PPE Winter Forecast 2020/21</li> <li>EU Exit Preparation Meetings</li> <li>COVID-19 Pandemic Surge Plan</li> <li>Procurement Influenza Pandemic Business Continuity Plan</li> </ul>	None	N/A	Management: Procurement Annual Report to Audit & Assurance Committee; Oxygen Supply Assurance report to Incident Control Team Apr '20; COVID-19 Governance Assurance Report to Board May '20 Independent assurance: Internal Audit Business Continuity and Emergency Planning Sep '18 – Significant Assurance; 2019/20 Counter Fraud, Bribery and Corruption Annual Report	Unknown impact on supply chain as a result of the Coronavirus outbreak Security of supplies due to: - Unknown impact of Brexit - Potential ban on exports to the UK from China Potential for fraud due to supply of substandard equipment/goods from alternative suppliers	Positive